Literature DB >> 15812581

Osteoprotegerin treatment impairs remodeling and apparent material properties of callus tissue without influencing structural fracture strength.

M Ulrich-Vinther1, T T Andreassen.   

Abstract

The influence of osteoprotegerin (OPG) treatment on callus formation, callus tissue structural strength, apparent material properties, and histology of tibia fractures in rats was investigated after 3 weeks and 8 weeks of healing. OPG was given intravenously (10 mg/kg twice weekly) during the entire observation period, and control animals with fractures received vehicle only. When compared with control fractures after 3 weeks of healing, OPG treatment reduced the number of osteoclasts in the callus tissue (93%, P < 0.001) and hampered resorption of genuine cortical bone in the fracture line; OPG treatment did not influence callus dimensions, callus bone mineral content (BMC), fracture structural strength, or callus tissue apparent material properties. When compared with control fractures after 8 weeks of healing; OPG treatment reduced the number of osteoclasts in callus tissue (92%, P < 0.001), augmented callus dimensions (anteriorposterior diameter: 12%, P = 0.034, mediolateral diameter: 13%, P = 0.013), and increased callus BMC (50%, P = 0.007); OPG treatment hampered deposition of new woven bone at the fracture line of the genuine cortical bone (new woven bone present in all vehicle animals, but only in 13% of the OPG-treated animals (P < 0.001)); OPG treatment did not influence structural strength of the fractures, but decreased apparent material properties of the callus tissue (ultimate stress: 51%, P < 0.001; elastic modulus: 42%, P = 0.033). The experiment demonstrates that OPG treatment does not influence the early callus expansion and fracture strength. However, during the subsequent period of remodelling, OPG treatment impairs the normal remodeling and consolidation processes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15812581     DOI: 10.1007/s00223-004-0126-9

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  14 in total

1.  Denosumab in postmenopausal osteoporosis: what the clinician needs to know.

Authors:  E Michael Lewiecki
Journal:  Ther Adv Musculoskelet Dis       Date:  2009-02       Impact factor: 5.346

Review 2.  Orthobiologics in the augmentation of osteoporotic fractures.

Authors:  J Tracy Watson; Daemeon A Nicolaou
Journal:  Curr Osteoporos Rep       Date:  2015-02       Impact factor: 5.096

Review 3.  Overview of skeletal repair (fracture healing and its assessment).

Authors:  Elise F Morgan; Anthony De Giacomo; Louis C Gerstenfeld
Journal:  Methods Mol Biol       Date:  2014

Review 4.  Optimising antiresorptive therapies in postmenopausal women: why do we need to give due consideration to the degree of suppression?

Authors:  Morten A Karsdal; Per Qvist; Claus Christiansen; László B Tankó
Journal:  Drugs       Date:  2006       Impact factor: 9.546

5.  Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing.

Authors:  Louis C Gerstenfeld; Daniel J Sacks; Megan Pelis; Zachary D Mason; Dana T Graves; Mauricio Barrero; Michael S Ominsky; Paul J Kostenuik; Elise F Morgan; Thomas A Einhorn
Journal:  J Bone Miner Res       Date:  2009-02       Impact factor: 6.741

6.  Local delivery of osteoprotegerin inhibits mechanically mediated bone modeling in orthodontic tooth movement.

Authors:  Matthew D Dunn; Chan Ho Park; Paul J Kostenuik; Sunil Kapila; William V Giannobile
Journal:  Bone       Date:  2007-05-08       Impact factor: 4.398

Review 7.  Cellular biology of fracture healing.

Authors:  Chelsea S Bahney; Robert L Zondervan; Patrick Allison; Alekos Theologis; Jason W Ashley; Jaimo Ahn; Theodore Miclau; Ralph S Marcucio; Kurt D Hankenson
Journal:  J Orthop Res       Date:  2018-11-30       Impact factor: 3.494

Review 8.  Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

Authors:  Ann E Kearns; Sundeep Khosla; Paul J Kostenuik
Journal:  Endocr Rev       Date:  2007-12-05       Impact factor: 19.871

9.  Impaired Fracture Healing Caused by Deficiency of the Immunoreceptor Adaptor Protein DAP12.

Authors:  Masayuki Kamimura; Yu Mori; Akiko Sugahara-Tobinai; Toshiyuki Takai; Eiji Itoi
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

Review 10.  Emerging treatments for postmenopausal osteoporosis - focus on denosumab.

Authors:  Piet Geusens
Journal:  Clin Interv Aging       Date:  2009-06-09       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.